filmov
tv
Cisplatin-Based Therapy in Muscle-Invasive Bladder Cancer

Показать описание
In this segment, Dean F. Bajorin, MD, and Evan Y. Yu, MD, examine the use of cisplatin-based regimens in treating muscle-invasive bladder cancer.
Cisplatin-Based Therapy in Muscle-Invasive Bladder Cancer
Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Bladder Cancer
Case-Based Panel Discussion: Muscle-Invasive Bladder Cancer
Neoadjuvant Immune Checkpoint Inhibition for Muscle Invasive Bladder Cancer
BLASST-1: nivolumab + gemcitabine-cisplatin before radical cystectomy in muscle-invasive BC
Immunotherapy for Muscle Invasive Bladder Cancer
Risk-enabled therapy after initiating neoadjuvant chemo allows active surveillance of some MIBC
Phase-2 trial of gemcitabine, cisplatin + nivolumab with selective bladder sparing in MIBC patients
Neoadjuvant sacituzumab govitecan for muscle-invasive bladder cancer
Gene Mutations as Predictive Biomarkers for Cisplatin-Based Chemotherapy Response in Bladder Cancer
Cisplatin-Based Chemotherapy Regimens for Bladder Cancer - Bladder Cancer Video Library
Cisplatin-Ineligible Treatment Options for Advanced Bladder Cancer - Bladder Cancer Video Library
Muscle Invasive Bladder Cancer 2018 Guidelines
The Evolution of First Line Therapy in Cisplatin-Ineligible Patients - Bladder Cancer Video Library
CtDNA in Non-Muscle Invasive Bladder Cancer - Bladder Cancer Video Library
ADCs for the treatment of bladder cancer in the neoadjuvant setting
CtDNA in Muscle Invasive Bladder Cancer - Bladder Cancer Video Library
Dr. O'Neil on Standard of Care in Muscle-Invasive Bladder Cancer
Case 2: Cisplatin-Ineligible Metastatic Bladder Cancer
Introduction: Neoadjuvant Chemotherapy in Bladder Cancer
Treating Relapsed Muscle-Invasive Bladder Cancer
Definitive Radiation-Based Therapy for Muscle Invasive Bladder Cancer
Advancing Therapies in Muscle-Invasive Bladder Cancer
Phase II study of neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with MIBC
Комментарии